2. 筋萎縮性側索硬化症
[臨床試験数:508,薬物数:530(DrugBank:146),標的遺伝子数:170,標的パスウェイ数:221

Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02881489
(ClinicalTrials.gov)
November 201522/4/2016Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Patients With Amyotrophic Lateral SclerosisEvaluation of Mesenchymal Stem Cell Culturing Protocols in the Treatment of Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisOther: Biological: Cell-based therapyUniversity of Warmia and MazuryNULLEnrolling by invitation18 Years65 YearsBoth30Phase 1NULL
2NCT02881476
(ClinicalTrials.gov)
November 201522/4/2016Therapeutic Treatment of Amyotrophic Lateral SclerosisApplication of Wharton's Jelly-derived Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisOther: Biological: Cell-based therapyUniversity of Warmia and MazuryNULLEnrolling by invitation18 Years65 YearsBoth30Phase 1NULL
3NCT02290886
(ClinicalTrials.gov)
July 20149/10/2014A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis LateralA Multicenter Phase I/II Clinical Trial, Randomized, Controlled With Placebo, Triple Blind to Evaluate Safety, and Indications of Efficiency of the Intravenous Administration of the Therapy With 3 Doses of MSC in Patients With ASL Moderated to SevereAmyotrophic Lateral SclerosisOther: Intravenous administration of placebo;Drug: Intravenous administration of 1 million of MSC;Drug: Intravenous administration of 2 million of MSC;Drug: Intravenous administration of 4 million of MSCAndalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y SaludIniciativa Andaluza en Terapias AvanzadasActive, not recruiting18 YearsN/AAll52Phase 1;Phase 2Spain
4NCT02193893
(ClinicalTrials.gov)
January 201016/7/2014Biological Treatment of Amyotrophic Lateral SclerosisSafety/Efficacy Study for the Biological Treatment of Amyotrophic Lateral Sclerosis With Autologous Stem/Progenitor CellsAmyotrophic Lateral SclerosisOther: Biological: Cell-based therapeutics;Other: Symptomatic treatment of ALSPomeranian Medical University SzczecinNULLEnrolling by invitation18 Years65 YearsBoth50Phase 1Poland